Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy
暂无分享,去创建一个
L. Servais | J. Hogrel | P. Carlier | N. Azzabou | T. Voit | T. Gidaro | V. Decostre | A. Le Moing | C. Wary | M. Annoussamy | C. Lilien | I. Ledoux | G. Ollivier | A. Moraux | A. Canal | Nacera Reguiba | R. Cardaş
[1] L. Servais,et al. Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype , 2015, Journal of neuromuscular diseases.
[2] J. Mendell,et al. Reliability and validity of active‐seated: An outcome in dystrophinopathy , 2015, Muscle & nerve.
[3] Ruzena Bajcsy,et al. Upper extremity 3‐dimensional reachable workspace analysis in dystrophinopathy using Kinect , 2015, Muscle & nerve.
[4] L. Servais,et al. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy , 2015, NMR in biomedicine.
[5] Jean-Yves Hogrel,et al. Grip strength measured by high precision dynamometry in healthy subjects from 5 to 80 years , 2015, BMC Musculoskeletal Disorders.
[6] L. Servais,et al. Upper Limb Evaluation and One-Year Follow Up of Non-Ambulant Patients with Spinal Muscular Atrophy: An Observational Multicenter Trial , 2015, PloS one.
[7] P. Carlier,et al. Validation of a generic approach to muscle water T2 determination at 3T in fat‐infiltrated skeletal muscle , 2015, Journal of magnetic resonance imaging : JMRI.
[8] L. Servais,et al. Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial , 2015, PloS one.
[9] C. Senesac,et al. Longitudinal Evaluation of Muscle Composition Using Magnetic Resonance in 4 Boys With Duchenne Muscular Dystrophy: Case Series , 2015, Physical Therapy.
[10] R. Kotin,et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] R. Finkel,et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS , 2014, Neurology.
[12] W. Triplett,et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: Effects of age and disease progression , 2014, Neuromuscular Disorders.
[13] M. Versluis,et al. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy , 2014, Neuromuscular Disorders.
[14] Elizabeth Vroom,et al. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy , 2013, Developmental medicine and child neurology.
[15] R. Finkel,et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. , 2013, Radiology.
[16] M. Reijnierse,et al. Comparison of dixon and T1‐weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients , 2013, Journal of magnetic resonance imaging : JMRI.
[17] B. Wong,et al. Analysis of fatty infiltration and inflammation of the pelvic and thigh muscles in boys with Duchenne muscular dystrophy (DMD): grading of disease involvement on MR imaging and correlation with clinical assessments , 2013, Pediatric Radiology.
[18] O. Bieri,et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy , 2013, Journal of Neurology.
[19] W. Triplett,et al. T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross‐sectional study of lower leg muscles in 5–15‐year‐old boys with Duchenne muscular dystrophy , 2013, NMR in biomedicine.
[20] T. Voit,et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients , 2013, Neuromuscular Disorders.
[21] A. Goyenvalle,et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] N. Azzabou,et al. Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs , 2012, Neuromuscular Disorders.
[23] P. Carlier,et al. Splitting of Pi and other 31P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy , 2012, NMR in biomedicine.
[24] J. Hogrel,et al. Stature is an essential predictor of muscle strength in children , 2012, BMC Musculoskeletal Disorders.
[25] M. Gaeta,et al. Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments , 2012, Skeletal Radiology.
[26] B. Tseng,et al. Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study , 2012, Skeletal Radiology.
[27] C. Senesac,et al. Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy , 2012, Neuromuscular Disorders.
[28] E. Mercuri,et al. Muscle histology vs MRI in Duchenne muscular dystrophy , 2011, Neurology.
[29] Krista Vandenborne,et al. Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy. , 2010, Archives of physical medicine and rehabilitation.
[30] Bernard J. Dardzinski,et al. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. , 2010, Radiology.
[31] U. Sharma,et al. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. , 2010, Magnetic resonance imaging.
[32] J. Fermanian,et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure , 2010, Developmental medicine and child neurology.
[33] Fabiana Luisa Mattar,et al. Hand weakness in Duchenne muscular dystrophy and its relation to physical disability , 2008, Neuromuscular Disorders.
[34] A. Connolly,et al. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging , 2005, Skeletal Radiology.
[35] A L Hull,et al. Assessment of hand function in Duchenne muscular dystrophy. , 1993, Archives of physical medicine and rehabilitation.
[36] P. Zaniol,et al. 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers Altered rate of phosphate transport , 1992, Journal of the Neurological Sciences.
[37] B. Chance,et al. 31P NMR studies in Duchenne muscular dystrophy , 1987, Neurology.
[38] D. Wilkie,et al. Muscle energy metabolism in duchenne dystrophy studied by 31P‐NMR: Controlled trials show no effect of allopurinol or ribose , 1985, Muscle & nerve.
[39] G K Radda,et al. Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy. , 1982, British medical journal.
[40] Ishu Arpana,et al. T 2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases : a cross-sectional study of lower leg muscles in 5 – 15-year-old boys with Duchenne muscular dystrophy , 2013 .
[41] Vicente Gilsanz,et al. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. , 2008, AJR. American journal of roentgenology.